Abstract：
The current global epidemic of hypertension is not a disease in and of itself but rather a significant risk factor for serious cardiovascular conditions such as peripheral artery disease, heart failure, myocardial infarction, and stroke. Although many medications that work through various mechanisms of action are available on the market in conventional formulations to treat hypertension, these medications face significant difficulties with their bioavailability, dosing, and associated side effects, which significantly reduces the effectiveness of their therapeutic interventions. Numerous studies have shown that nanocarriers and nanoformulations can minimize the toxicity associated with high doses of the drug while greatly increasing the drug\'s bioavailability and reducing the frequency of dosing.
This review sheds light on the difficulties posed by traditional antihypertensive formulations and highlights the necessity of oral nanoparticulate systems to solve these issues. Because hypertension has a circadian blood pressure pattern, chronotherapeutics can be very important in treating the condition. On the other hand, nanoparticulate systems can be very important in managing hypertension.
摘要：
目前高血压在全球范围内的流行并不是一种疾病本身，而是严重心血管疾病如外周动脉疾病的重要危险因素。心力衰竭,心肌梗塞,和中风。尽管市场上有许多通过各种作用机制起作用的药物以常规配方可用于治疗高血压，这些药物的生物利用度面临着巨大的困难，给药,和相关的副作用，这大大降低了他们的治疗干预措施的有效性。大量研究表明，纳米载体和纳米制剂可以最大限度地减少与高剂量药物相关的毒性，同时大大提高药物的生物利用度并降低给药频率。
这篇综述阐明了传统抗高血压制剂带来的困难，并强调了口服纳米颗粒系统解决这些问题的必要性。因为高血压有昼夜节律的血压模式，计时疗法在治疗这种疾病中非常重要。另一方面,纳米颗粒系统在控制高血压方面可能非常重要。
